62.96
  Price0.82%   +0.51
(After Hours: 62.80 -0.16 -0.25%)
Aug-10-22 05:13AM 3 Healthcare Stocks With High Profit MarginsThe Motley Fool
Aug-08-22 10:58AM How Many Small-Cap Stocks Are There? ##YEAR##The Motley Fool
Aug-07-22 10:45AM 2 Reasons This Beaten-Down Stock Could Be About to ReboundThe Motley Fool
Aug-04-22 06:20AM Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now?Zacks Investment Research
Aug-03-22 11:51AM Why Gilead Sciences Stock Is Jumping TodayThe Motley Fool
09:53AM Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook UppedZacks Investment Research
Aug-03-22 06:20AM Should VanEck Morningstar Wide Moat ETF (MOAT) Be on Your Investing Radar?Zacks Investment Research
Aug-02-22 11:00AM Gilead Sciences (GILD) Q2 2022 Earnings Call TranscriptThe Motley Fool
05:25AM Gilead Sciences (GILD) Beats Q2 Earnings and Revenue EstimatesZacks Investment Research
Aug-02-22 11:52AM Is a Beat in Store for BioNTech (BNTX) This Earnings Season?Zacks Investment Research
Aug-01-22 01:59AM Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & MoreZacks Investment Research
12:31PM Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?Zacks Investment Research
Aug-01-22 12:29PM Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?Zacks Investment Research
12:07PM Novo Nordisk (NVO) to Report Q2 Earnings: What's in the Cards?Zacks Investment Research
Aug-01-22 11:06AM With An Economic Recession Looming, Is An Earnings Recession To Follow?Investing.com
09:47AM Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?Zacks Investment Research
Aug-01-22 05:16AM July’s Big Rally Could Continue, But Consider The Risks Investing.com
Jul-31-22 07:45AM 2 Cheap Dividend Stocks Yielding More Than 4%The Motley Fool
Jul-29-22 10:20AM What is in Store for Regeneron (REGN) This Earnings Season?Zacks Investment Research
Jul-28-22 10:10AM Is a Beat in Store for Gilead (GILD) in This Earnings Season?Zacks Investment Research
Jul-27-22 11:15AM Biotech Stock Roundup: BMY, BIIB's Q2 Earnings, GILD's Updates & MoreZacks Investment Research
10:51AM Will AstraZeneca (AZN) Deliver a Beat This Earnings Season?Zacks Investment Research
Jul-27-22 10:01AM Earnings Preview: Bionano Genomics, Inc. (BNGO) Q2 Earnings Expected to DeclineZacks Investment Research
Jul-26-22 02:32AM Should You Buy Beaten-Down Biotech Stocks & ETFs?Zacks Investment Research
10:01AM Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research
Jul-25-22 12:03PM Gilead (GILD) Gets Positive CHMP Opinion for Veklury & TecartusZacks Investment Research
Jul-19-22 06:20AM Should You Invest in the VanEck Biotech ETF (BBH)?Zacks Investment Research
Jul-15-22 08:55AM This New Regulation Could Juice Pfizer Stock Even MoreThe Motley Fool
Jul-14-22 11:37AM Humanigen (HGEN) Plunges as COVID Study Fails to Meet GoalZacks Investment Research
07:04AM Pandemic is still a public health emergency, warns WHO, urging greater surveillance including testing and sequencingMarketWatch
Jul-13-22 11:04AM Pandemic is still a public health emergency, warns WHO, urging greater surveillance including testing and sequencingMarketWatch
10:04AM WHO warns pandemic still a public health emergency, urges greater surveillance including testing and sequencingMarketWatch
Jul-13-22 06:20AM Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?Zacks Investment Research
Jul-10-22 11:00AM How to Earn $10,000 a Year in Passive Retirement IncomeThe Motley Fool
Jul-09-22 10:23AM This Company Could Ease the Pain in a Bear MarketThe Motley Fool
Jul-08-22 11:44AM VERU's Shares Jump on Successful COVID-19 Study ResultsZacks Investment Research
Jul-07-22 08:19AM Zacks Market Edge Highlights: ExxonMobil, Chevron, Philip Morris International, Gilead Sciences and General MillsZacks Investment Research
Jul-06-22 03:33AM Q2 Earnings: Energy and What Else?Zacks Investment Research
Jul-04-22 07:00AM Is Gilead Sciences' Dividend Safe?The Motley Fool
06:20AM Should You Invest in the iShares Biotechnology ETF (IBB)?Zacks Investment Research
Jul-01-22 10:56AM Pfizer (PFE) Seeks FDA Nod for Its Oral Antiviral COVID PillZacks Investment Research
Jun-29-22 11:51AM Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & MoreZacks Investment Research
10:28AM Gilead's (GILD) Yescarta Gets EC Nod for Follicular LymphomaZacks Investment Research
Jun-28-22 08:49AM Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDAZacks Investment Research
Jun-27-22 01:21AM Gilead (GILD) HIV Candidate Gets Positive CHMP RecommendationZacks Investment Research
01:06AM Bristol Myers (BMY) Breyanzi Gets FDA Nod for Label ExpansionZacks Investment Research
Jun-26-22 05:57AM 3 Top Dividend Stocks for Generating Passive IncomeThe Motley Fool
Jun-24-22 12:30PM Gilead (GILD) Announces Positive Data on Hepcludex for HDVZacks Investment Research
Jun-23-22 11:47AM Top Stock Reports for Tesla, Broadcom & AnthemZacks Investment Research
11:00AM 2 Beaten-Down Dividend Stocks That Are Now Yielding 5%The Motley Fool
Gilead Sciences, Inc. discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a PI3K delta inhibitor for certain blood cancers; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and Lexiscan, an injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging. In addition, the company offers Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B; AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, hematology/oncology, inflammation/respiratory diseases, and others. The company markets its products through its commercial teams; and in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company; Janssen Sciences Ireland UC; Japan Tobacco Inc.; Galapagos NV; Tango Therapeutics, Inc.; AELIX Therapeutics S.L.; and TARGET PharmaSolutions, Inc. The company was founded in 1987 and is headquartered in Foster City, California.
Cap:    |  Volume (24h):